Pirfenidone results "look great" says Summer Street

"We believe that the data was impressive and should lead to FDA approval as well as increased sales in the EU," says the team at Summer Street, commenting on the Phase III trial results for InterMune's (ITMN +158.4%) Pirfenidone.

"The trial met its primary endpoint, improved force vital capacity (p<0.000001). The company reported the trial also met several endpoints including six-minute walk test distance change (p=0.0360) and progression-free survival (p=0.0001). Pooled data from the ASCEND trial and the previous two phase III CAPACITY trials showed an statistically significant improvement in mortality (HR=0.52, log rank p=0.0107)."

Oppenheimer boosts its price target to $42 from $19.

From other sites
Comments (1)
  • jacosa
    , contributor
    Comments (224) | Send Message
    Unfortunate wording could seriously mislead readers. The primary endpoint was not "improved" forced vital capacity (the drug slows disease progression, but does not reverse damage). The primary endpoint is "predicted" forced vital capacity (a bit of medicalese that expands to change in measured forced vital capacity compared to 'predicted' [From charts, in the ordinary sense, FVC])
    25 Feb 2014, 02:16 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs